1. Protein Tyrosine Kinase/RTK
  2. c-Kit
    FLT3
    FGFR
    VEGFR
    PDGFR

Dovitinib (Synonyms: CHIR-258; TKI258; TKI-258; TKI 258; CHIR258; CHIR 258)

Cat. No.: HY-50905 Purity: 99.31%
Handling Instructions

Dovitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively.

For research use only. We do not sell to patients.

Dovitinib Chemical Structure

Dovitinib Chemical Structure

CAS No. : 405169-16-6

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 106 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
10 mg USD 96 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
50 mg USD 288 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
100 mg USD 480 In-stock
Stock in the United States
Estimated Time of Arrival: December 31
200 mg USD 840 In-stock
Stock in the United States
Estimated Time of Arrival: December 31
500 mg USD 1560 In-stock
Stock in the United States
Estimated Time of Arrival: December 31
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

Other Forms of Dovitinib:

View All FGFR Isoform Specific Products:

View All VEGFR Isoform Specific Products:

View All PDGFR Isoform Specific Products:

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Dovitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively.

IC50 & Target[1]

FGFR1

8 nM (IC50)

FGFR3

9 nM (IC50)

VEGFR1

1 nM (IC50)

VEGFR2

13 nM (IC50)

VEGFR3

8 nM (IC50)

PDGFRα

27 nM (IC50)

PDGFRβ

210 nM (IC50)

FLT3

1 nM (IC50)

c-Kit

2 nM (IC50)

In Vitro

Dovitinib potently inhibits the FGF-stimulated growth of WT and F384L-FGFR3-expressing B9 cells with IC50 values of 25 nM. B9-MINV cells are resistant to the inhibitory activity of Dovitinib at concentrations up to 1 μM. Dovitinib inhibits cell proliferation of KMS11 (FGFR3-Y373C), OPM2 (FGFR3-K650E), and KMS18 (FGFR3-G384D) cells with IC50 of values of 90 nM (KMS11 and OPM2) and 550 nM, respectively[1]. Dovitinib significantly reduces the basal phosphorylation levels of FGFR-1, FGFR substrate 2α (FRS2-α) and ERK1/2 but not Akt in both SK-HEP1 and 21-0208 cells[2]. Dovitinib enhances the BMP-2-induced alkaline phosphatase (ALP) induction, which is a representative marker of osteoblast differentiation. Dovitinib also stimulates the translocation of phosphorylated Smad1/5/8 into the nucleus and phosphorylation of mitogen-activated protein kinases, including ERK1/2 and p38[3]. Dovitinib strongly inhibits both the interaction of TNIK with ATP (Ki, 13 nM) and the activation of Wnt signaling effectors such as β-catenin and TCF4. Dovitinib also induces caspase-dependent apoptosis in IM-9 cells without significant cytotoxicity in PBMCs[4].

In Vivo

Dovitinib (10 mg/kg, 30 mg/kg, 60 mg/kg, p.o.) shows significant antitumor effect in the KMS11-bearing mice model, and the growth inhibition is 48%, 78.5%, and 94% in the 10 mg/kg, 30 mg/kg, and 60 mg/kg treatment arms, respectively, compared with the placebo-treated mice[1]. Dovitinib (50 and 75 mg/kg) results in 97% and 98% tumor growth inhibition, respectively, and the maximal efficacy is at 50 mg/kg[2].

Clinical Trial
References
Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 2.5482 mL 12.7411 mL 25.4823 mL
5 mM 0.5096 mL 2.5482 mL 5.0965 mL
10 mM 0.2548 mL 1.2741 mL 2.5482 mL
Please refer to the solubility information to select the appropriate solvent.
Kinase Assay
[1]

The inhibitory concentration of 50% (IC50) values for the inhibition of RTKs by Dovitinib are determined in a time-resolved fluorescence (TRF) or radioactive format, measuring the inhibition by Dovitinib of phosphate transfer to a substrate by the respective enzyme. The kinase domains of FGFR3, FGFR1, PDGFR-β, and VEGFR1-3 are assayed in 50 mM HEPES (N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid), pH 7.0, 2 mM MgCl2, 10 mM MnCl2 1 mM NaF, 1 mM dithiothreitol (DTT), 1 mg/mL bovine serum albumin (BSA), 0.25 μM biotinylated peptide substrate (GGGGQDGKDYIVLPI), and 1 to 30 μM adenosine triphosphate (ATP) depending on the Km for the respective enzyme. ATP concentrations are at or just below Km. For c-KIT and FLT3 reactions the pH is raised to 7.5 with 0.2 to 8 μM ATP in the presence of 0.25 to 1 μM biotinylated peptide substrate (GGLFDDPSYVNVQNL). Reactions are incubated at room temperature for 1 to 4 hours and the phosphorylated peptide captured on streptavidin-coated microtiter plates containing stop reaction buffer (25 mM EDTA [ethylenediaminetetraacetic acid], 50 mM HEPES, pH 7.5). Phosphorylated peptide is measured with the DELFIA TRF system using a Europium-labeled antiphosphotyrosine antibody PT66. The concentration of Dovitinib for IC50 is calculated using nonlinear regression with XL-Fit data analysis software version 4.1. Inhibition of colony-stimulating factor-1 receptor (CSF-1R), PDGFR-α, insulin receptor (InsR), and insulin-like growth factor receptor 1 (IGFR1) kinase activity is determined using the IC50 Profiler Express service. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay
[1]

Dovitinib is dissolved in DMSO at a stock concentration of 20 mM.

Cell viability is assessed by 3-(4,5-dimethylthiazol)-2,5-diphenyl tetrazolium (MTT) dye absorbance according to the manufacturer's instructions. Cells are seeded in 96-well plates at a density of 5000 (B9 cells) or 20 000 (MM cell lines) cells per well. Cells are incubated with 30 ng/mL aFGF and 100 μg/mL heparin or 1% IL-6 where indicated and increasing concentrations of Dovitinib. For each concentration of Dovitinib, 10-μL aliquots of drug or DMSO diluted in culture medium is added. For drug combination studies, cells are incubated with 0.5 μM dexamethasone, 100 nM Dovitinib, or both simultaneously where indicated. To evaluate the effect of Dovitinib on growth of MM cells adherent to BMSCs, 10 000 KMS11 cells are cultured on BMSC-coated 96-well plates in the presence or absence of Dovitinib. Plates are incubated for 48 to 96 hours. For assessment of macrophage colony-stimulating factor (M-CSF)-mediated growth, 5000 M-NFS-60 cells/well are incubated with serial dilutions of CHIR-25 ZS8 with 10 ng/mL M-CSF and without granulocyte-macrophage colony-stimulating factor (GM-CSF). After 72 hours cell viability is determined using Cell Titer-Glo Assay. Each experimental condition is performed in triplicate. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[1]

Dovitinib is formulated in 5 mM citrate buffer.

The xenograft mouse model is prepared as previously described.27 Briefly, 6- to 8-week-old female BNX mice are inoculated subcutaneously into the right flank with 3×107 KMS11 cells in 150 μL IMDM, together with 150 μL Matrigel basement membrane matrix. Treatment is initiated when tumors reach volumes of 200 mm3 at which time mice are randomized to receive 10, 30, or 60 mg/kg Dovitinib or 5 mM citrate buffer. Dosing is performed daily for 21 days by gavage. Eight to 10 mice are included in each treatment group. Caliper measurements are performed twice weekly to estimate tumor volume, using the formula: 4π/3 × (width/2)2 × (length/2). One-way analysis of variance is used to compare differences between vehicle- and Dovitinib-treated groups. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

392.43

Formula

C₂₁H₂₁FN₆O

CAS No.

405169-16-6

SMILES

O=C1NC(C=CC=C2F)=C2C(N)=C1C3=NC4=CC=C(N5CCN(C)CC5)C=C4N3

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: 25 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Dovitinib
Cat. No.:
HY-50905
Quantity: